Many malignancies develop as a result of genetic alterations in individual cells. These gene mutations often cause altered proteins that give new, growth-promoting properties to the cell. A prime example for this principle is a cancer-related altered form of the IDH1 enzyme that was initially discovered in certain malignant brain tumors.
Scientists had noticed that mutations in isocitrate dehydrogenase (IDH) 1 almost always occur at position 132 of the enzyme's chain of amino acids. This replacement causes a specific cancer-promoting metabolic product to accumulate in the cells. Non-mutated IDH enzymes in healthy cells do not produce this metabolite.
"This prompted the idea of developing an agent that inhibits position 132-mutant IDH1," said Stefan Pusch from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ). He added: "Our goal is to develop a drug that acts on cancer cells while it does not influence healthy cells with the normal enzyme."
In a research alliance with Bayer AG, the researchers from the DKFZ and Bayer jointly succeeded in finding a substance that is presumed to be highly selective. The investigational compound, called BAY1436032, is currently being examined in comprehensive preclinical tests for its safety and effectiveness.
Leukemia and brain cancer in mice slowed down
The 132 mutation of IDH1 has been found by now not only in various types of brain cancer (oligodendroglioma, diffuse astrocytoma and a smaller portion of glioblastomas) but also in approximately ten percent of acute myeloid leukemias (AML) as well as in bile duct cancer and certain malignant bone tumors. In two currently published studies, the Heidelberg researchers have now demonstrated the preclinical activity of BAY1436032 against AML and brain tumors (astrocytoma) in mice.
Under treatment with BAY1436032, mice that had been transplanted human astrocytoma cells survived significantly longer than untreated fellows. The agent, which can be administered with the food, substantially reduced the levels of the cancer-promoting metabolite in the cancer. "Even at high doses the animals tolerated the treatment well," said Andreas von Deimling, who is the head of a Clinical Cooperation Unit at the DKFZ and at Heidelberg University Hospital. "BAY1436032 really seems to act specifically on the mutated IDH1 in the cancer cells."
Tests of the agent against AML were also successful. Mice that had received IDH1-mutant human leukemia cells survived longer when treated with BAY1436032 than untreated animals did. Furthermore, the leukemia stem cells in their bone marrow were significantly reduced.
Cancer cells lose stem-cell properties
"There is evidence to suggest that BAY1436032 does not act cytotoxic, but may cause tumor cells to mature into normal blood cells instead," stated hemato-oncologist and scientist Alwin Krämer, who leads a Clinical Cooperation Unit of the German Cancer Research Center and Heidelberg University Hospital. Von Deimling, who led the preclinical study in gliomas, confirmed this observation: "The cancer cells in the mice under investigation lost their dangerous stem-cell characteristics and developed into precursors of normal brain cells".
As a couple of different mutations at amino acid position 132 of IDH1 are known, the research team also tested the effectiveness of the investigational compound against these mutational variants. In biochemical and cell culture assays, they could show that BAY1436032 is effective against all known mutational variants at position 132. In addition, there are indications that BAY1436032 may be able to cross the blood-brain barrier.
Following these promising preclinical results, a first clinical trial is currently being conducted at the Neurology Department of Heidelberg University Hospital. The trial comprises patients with glioma and other solid tumors with proven IDH1 mutation. The goal is to determine the tolerability of BAY1436032 and the appropriate dose. "Innovative therapies are greatly needed here," von Deimling said, "because therapy-resistant astrocytomas often turn into highly aggressive tumors that cannot be treated effectively with the drugs that are available at the present time."
In addition, an international clinical trial led by Alwin Krämer will shortly be launched to study the tolerability and the appropriate dose of BAY1436032 against IDH1 mutant AML.
A Chaturvedi, L Herbst, S Pusch, L Klett, R Goparaju, D, Stichel, S Kaulfuss, O Panknin, K Zimmermann, L Toschi, R Neuhaus, A, Haegebarth, H Rehwinkel, H Hess-Stumpp, M Bauser, T Bochtler, E A Struys, A, Sharma, A Bakkali, R Geffers, M M Araujo-Cruz, F Thol, R Gabdoulline, A, Ganser, A D Ho, A von Deimling, K Rippe, M Heuser, A Krämer: Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. Leukemia, 2017; DOI: 10.1038/leu.2017.46.
Stefan Pusch, Sonja Krauser, Viktoria Fischer, Jörg Balss, Martina Ott, Daniel Schrimpf, David Capper, Felix Sahm, Jessica Eisel, Ann-Christin Beck, Manfred Jugold, Viktoria Eichwald, Stefan Kaulfuss, Olaf Panknin, Hartmut Rehwinkel, Katja Zimmermann, Roman C. Hillig, Judith Guenther, Luisella Toschi, Roland Neuhaus, Andrea Haegebart, Holger Hess-Stumpp, Markus Bauser, Wolfgang Wick, Andreas Unterberg, Christel Herold-Mende, Michael Platten, Andreas von Deimling: Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathologica, 2017 DOI 10.1007/s00401-017-1677-y
The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public.
Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.
Dr. Sibylle Kohlstädt | EurekAlert!
Study tracks inner workings of the brain with new biosensor
16.08.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn
Foods of the future
15.08.2018 | Georg-August-Universität Göttingen
New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference
Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...
Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...
Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.
When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...
Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.
Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....
Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.
Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...
17.08.2018 | Event News
08.08.2018 | Event News
27.07.2018 | Event News
17.08.2018 | Physics and Astronomy
17.08.2018 | Information Technology
17.08.2018 | Life Sciences